2018
Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial
Gillison ML, Trotti AM, Harris J, Eisbruch A, Harari PM, Adelstein DJ, Jordan RCK, Zhao W, Sturgis EM, Burtness B, Ridge JA, Ringash J, Galvin J, Yao M, Koyfman SA, Blakaj DM, Razaq MA, Colevas AD, Beitler JJ, Jones CU, Dunlap NE, Seaward SA, Spencer S, Galloway TJ, Phan J, Dignam JJ, Le QT. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. The Lancet 2018, 393: 40-50. PMID: 30449625, PMCID: PMC6541928, DOI: 10.1016/s0140-6736(18)32779-x.Peer-Reviewed Original ResearchConceptsHPV-positive oropharyngeal carcinomaProgression-free survivalOverall survivalNon-inferiority trialCisplatin groupCetuximab groupOropharyngeal carcinomaSevere toxicityEligibility criteriaPositive oropharyngeal squamous cell carcinomaHuman papillomavirus-positive oropharyngeal cancerNational Cancer Institute-USAZubrod performance status 0Oropharyngeal squamous cell carcinomaAdequate bone marrowPerformance status 0Replacement of cisplatinZubrod performance statusInferior overall survivalTobacco smoking historyAmerican Joint CommitteeNon-inferiority criteriaSquamous cell carcinomaStandard of careNon-inferiority margin
2010
Increased Recurrences Using Intensity-Modulated Radiation Therapy in the Postoperative Setting
Turaka A, Li T, Sharma NK, Li L, Nicolaou N, Mehra R, Burtness B, Cohen RB, Lango MN, Horwitz EM, Ridge JA, Feigenberg SJ. Increased Recurrences Using Intensity-Modulated Radiation Therapy in the Postoperative Setting. American Journal Of Clinical Oncology 2010, 33: 599-603. PMID: 21063195, DOI: 10.1097/coc.0b013e3181c4c3cc.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge DistributionAgedAged, 80 and overCarcinoma, Squamous CellCohort StudiesFemaleHead and Neck NeoplasmsHumansIncidenceMaleMiddle AgedNeck DissectionNeoplasm Recurrence, LocalNeoplasm StagingPostoperative CarePostoperative PeriodPrognosisRadiotherapy DosageRadiotherapy, Intensity-ModulatedRetrospective StudiesRisk AssessmentSex DistributionSurvival AnalysisTreatment FailureConceptsPatterns of failurePostoperative therapyRadiation therapyLocal failureMarginal failureNeck cancerRegional failureRetrospective single-institution studyFox Chase Cancer CenterHigh-risk PTVLocoregional failure rateAddition of chemotherapySingle-institution studySquamous cell carcinomaIntensity-modulated radiation therapyPersistence of diseaseLow-risk PTVConcurrent cisplatinCurative intentDefinitive radiationDefinitive RTNodal recurrencePostoperative settingMedian ageNodal stageNonsurgical management of oropharyngeal, laryngeal, and hypopharyngeal cancer: The Fox Chase Cancer Center experience
Andrews G, Lango M, Cohen R, Feigenberg S, Burtness B, Mehra R, Ahmed S, Nicolaou N, Gaughan J, Ridge JA. Nonsurgical management of oropharyngeal, laryngeal, and hypopharyngeal cancer: The Fox Chase Cancer Center experience. Head & Neck 2010, 33: 1433-1440. PMID: 21928415, DOI: 10.1002/hed.21615.Peer-Reviewed Original ResearchMeSH KeywordsCancer Care FacilitiesCarcinoma, Squamous CellChemoradiotherapy, AdjuvantCohort StudiesDisease-Free SurvivalFemaleHumansHypopharyngeal NeoplasmsLaryngeal NeoplasmsMaleMiddle AgedNeoplasm Recurrence, LocalOropharyngeal NeoplasmsProportional Hazards ModelsRadiotherapy, ConformalRadiotherapy, Intensity-ModulatedRetrospective StudiesSalvage TherapySmokingConceptsSurvival of patientsNumber of patientsOropharyngeal cancerHypopharyngeal cancerT classificationLaryngeal cancerFox Chase Cancer Center experienceRetrospective single-institution cohort studyMultivariate analysisSingle-institution cohort studyRecurrent oropharyngeal cancerCancer Center experienceRecurrence-free survivalSubset of patientsLaryngeal cancer patientsDisease-related deathEarly T classificationHypopharyngeal cancer treatmentChemotherapy useCurative intentLocoregional controlCohort studyCurrent smokersOverall survivalSalvage surgeryUse of a Conventional Low Neck Field (LNF) and Intensity-Modulated Radiotherapy (IMRT): No Clinical Detriment of IMRT to an Anterior LNF During the Treatment of Head-and Neck-Cancer
Turaka A, Li T, Nicolaou N, Lango MN, Burtness B, Horwitz EM, Ridge JA, Feigenberg SJ. Use of a Conventional Low Neck Field (LNF) and Intensity-Modulated Radiotherapy (IMRT): No Clinical Detriment of IMRT to an Anterior LNF During the Treatment of Head-and Neck-Cancer. International Journal Of Radiation Oncology • Biology • Physics 2010, 79: 65-70. PMID: 20385457, PMCID: PMC3339153, DOI: 10.1016/j.ijrobp.2009.10.034.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic AgentsCarcinoma, Squamous CellChi-Square DistributionCombined Modality TherapyDisease-Free SurvivalFemaleFollow-Up StudiesGastrostomyHead and Neck NeoplasmsHumansLinear ModelsLymph Node ExcisionMaleMiddle AgedRadiotherapy DosageRadiotherapy, Intensity-ModulatedRetrospective StudiesTreatment FailureConceptsIntensity-modulated radiotherapyLow-neck fieldLower neckDisease-free survival ratesPercutaneous endoscopic gastrostomy tubeNeck fieldSingle-institution studySquamous cell carcinomaLog-rank testTreatment of headAnterior photon fieldAnterior low-neck fieldClinical detrimentCurative intentMedian ageClinical outcomesGastrostomy tubeNeck diseasePEG tubeCell carcinomaNeck cancerPhysician preferenceRegional failureStage IIIPatients